News | May 29, 2024
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Additional data from APPRAISE ATP trial reinforce modular therapy approach
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
With this, for all our USFDA facilities, EIRs are in place
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Subscribe To Our Newsletter & Stay Updated
